Abstract
Since long-acting somatostatin preparations have become available, they have been used for the treatment of acromegaly with great success [1, 2, 5, 6]. The greatest experience has been obtained with the octapeptide analogue, Sandostatin®, which leads at a dosage of 50 μg s.c. to a significant decrease of GH levels lasting up to 8h [3, 6]. Dosages of 3 × 50 of 3 × 100 μg Sandostatin s.c. were shown to normalize GH secretion in 90% of acromegalic patients [2, 3] without serious side effects on carbohydrate metabolism and the gastrointestinal tract [1, 3–5, 7].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Chiodini PG, Cozzi R, Dallabonzana D, Oppizzi G, Verde G, Petroncini M, Liuzzi A, Del Pozo E (1987) Medical treatment of acromegaly with SMS 201-995, a Somatostatin analog: A comparison with bromocriptine. J Clin Endocrinol Metab 64: 447
Comi RJ, Gorden P (1987) The response of serum growth hormone levels to long-acting somatostatin analog SMS 201-995 in acromegaly. J Clin Endocrinol Metab 64: 37
Lamberts SWJ, Oosterom R, Neufeld M, Del Pozo E (1985) The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients. J Clin Endocrinol Metab 60: 1161
Lamberts SWJ, Uitterlinden P, Verleun T (1987) Relationship between growth hormone and somatomedin-C levels in untreated acromegaly, after surgery and radiotherapy and during medical therapy with sandostatin (SMS 201-995). Eur J Clin Invest 17: 354
Lamberts SWJ, Uitterlinden P, Verschoor L, van Dongen KJ, Del Pozo E (1985) Long-term treatment of acromegaly with the somatostatin analogue SMS 201–945. N Engl J Med 313: 1576
Lamberts SWJ, Zweeis M, Klijn, JGM, Van Vroonhoven CCJ, Stefanko SZ, Del Pozo E (1986) The sensitivity of growth hormone and prolactin secretion to the somatostatin analog SMS 201-995 in patiets with prolactinomas and acromegaly. Clin Endocrinol 25: 201
Lamberts SWJ, Zweens M, Verschoor L, Del Pozo E (1986) A comparison among the rrowth hormone-lowering effects in acromegaly of the somatostatin, nalogr SMS 201-995, bromocriptin, and the combination of both drugs. J Clin Endocrinol Metab 63:16
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Springer-Verlag, Berlin Heidelberg
About this paper
Cite this paper
Schopohl, J., Müller, O.A., von Werder, K. (1988). SMS 201–995 (Sandostatin®) Treatment of Therapy-Resistant Acromegaly. In: Lamberts, S.W.J. (eds) Sandostatin® in the Treatment of Acromegaly. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73694-0_26
Download citation
DOI: https://doi.org/10.1007/978-3-642-73694-0_26
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-73696-4
Online ISBN: 978-3-642-73694-0
eBook Packages: Springer Book Archive